Md Anderson Cancer Center

Clinical research site in Houston, Texas · 1515 HOLCOMBE BLVD, UNIT 1445, HOUSTON, TX 77030-4000 · (713) 745-0496 · Website

Part of MD Anderson Cancer Center

As of July 2026, 433 paid clinical trials are recruiting at Md Anderson Cancer Center in Houston, Texas. Active studies at this site cover conditions such as Colorectal Cancer, Breast Cancer and Ovarian Cancer. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: July 19, 2026.

Recruiting clinical trials at Md Anderson Cancer Center (433)

A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

for CRC (Colorectal Cancer)

67 locations incl. Tucson

Sponsor: Incyte Corporation

Sex: All·Age: 18+

Code: NCT07284849·Phase 3·Recruiting·Listed Dec 2025

Apply to this trial

A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

for Squamous Cell Carcinoma of Head and Neck

45 locations incl. Chandler

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT07276399·Phase 3·Recruiting·Listed Dec 2025

Apply to this trial

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma

for Multiple Myeloma

29 locations incl. Birmingham

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT07266441·Phase 2·Recruiting·Listed Dec 2025

Apply to this trial

A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

for Metastatic Castration-resistant Prostate Neoplasms

53 locations incl. La Jolla

Sponsor: Janssen Research & Development, LLC

Sex: Male·Age: 18+

Code: NCT07164443·Phase 3·Recruiting·Listed Sep 2025

Apply to this trial

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

for Large B-cell Lymphoma

37 locations incl. Gilbert

Sponsor: Lyell Immunopharma, Inc.

Sex: All·Age: 18+

Code: NCT07188558·Phase 3·Recruiting·Listed Sep 2025

Apply to this trial

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

for Triple Negative Breast Cancer

124 locations incl. Birmingham

Sponsor: Gilead Sciences

Sex: All·Age: 18+

Code: NCT05633654·Phase 3·Recruiting·Listed Dec 2022

Apply to this trial

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

for Carcinoma, Non-Small-Cell Lung

129 locations incl. Daphne

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT06667076·Phase 2·Recruiting·Listed Oct 2024

Apply to this trial

A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

for Colorectal Neoplasms

68 locations incl. Chandler

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT06750094·Phase 3·Recruiting·Listed Dec 2024

Apply to this trial

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

for Colorectal Neoplasms

79 locations incl. Gilbert

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT06662786·Phase 3·Recruiting·Listed Oct 2024

Apply to this trial

A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)

for Coronavirus Disease (COVID-19)

61 locations incl. Paradise Valley

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06667700·Phase 3·Recruiting·Listed Oct 2024

Apply to this trial

A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

for Chronic Lymphocytic Leukemia

37 locations incl. Birmingham

Sponsor: BeOne Medicines

Sex: All·Age: 18+

Code: NCT06973187·Phase 3·Recruiting·Listed May 2025

Apply to this trial

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

for NSCLC (Non-small Cell Lung Cancer)

43 locations incl. Birmingham

Sponsor: Revolution Medicines, Inc.

Sex: All·Age: 18+

Code: NCT06881784·Phase 3·Recruiting·Listed Mar 2025

Apply to this trial

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

for Large B-cell Lymphoma

60 locations incl. Gilbert

Sponsor: Allogene Therapeutics

Sex: All·Age: 18+

Code: NCT06500273·Phase 2·Recruiting·Listed Jul 2024

Apply to this trial

FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3

for Urinary Bladder Neoplasms

41 locations incl. Tucson

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT05614739·Phase 1·Recruiting·Listed Nov 2022

Apply to this trial

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

for Leukemia, Myeloid, Acute

51 locations incl. Birmingham

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT06852222·Phase 3·Recruiting·Listed Feb 2025

Apply to this trial

A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)

for Mantle Cell Lymphoma

41 locations incl. Birmingham

Sponsor: BeOne Medicines

Sex: All·Age: 18+

Code: NCT06742996·Phase 3·Recruiting·Listed Dec 2024

Apply to this trial

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

for Carcinoma, Non-Small-Cell Lung

48 locations incl. Gilbert

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06623422·Phase 3·Recruiting·Listed Oct 2024

Apply to this trial

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

for Multiple Myeloma

28 locations incl. Phoenix

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT05201781·Phase 4·Recruiting·Listed Jan 2022

Apply to this trial

Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body

for Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion

27 locations incl. Los Angeles

Sponsor: Bayer

Sex: All·Age: All ages

Code: NCT04142437·Recruiting·Listed Oct 2019

Apply to this trial

SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

for Glioma

42 locations incl. Birmingham

Sponsor: Nuvation Bio Inc.

Sex: All·Age: 18+

Code: NCT05303519·Phase 3·Recruiting·Listed Mar 2022

Apply to this trial

MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

for Pancreatic Ductal Adenocarcinoma

25 locations incl. Duarte

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT06586515·Phase 1·Recruiting·Listed Sep 2024

Apply to this trial

A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

for Triple Negative Breast Cancer

26 locations incl. Phoenix

Sponsor: Day One Biopharmaceuticals, Inc.

Sex: All·Age: 18+

Code: NCT05377996·Phase 1, Phase 2·Recruiting·Listed May 2022

Apply to this trial

Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

for Metastatic Breast Cancer

31 locations incl. Scottsdale

Sponsor: LeonaBio

Sex: All·Age: 18+

Code: NCT05696626·Phase 3·Recruiting·Listed Jan 2023

Apply to this trial

A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)

for Acute Leukemia

23 locations incl. Duarte

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 2+

Code: NCT04811560·Phase 1, Phase 2·Recruiting·Listed Mar 2021

Apply to this trial

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

for B-cell Malignancy

28 locations incl. Birmingham

Sponsor: BeOne Medicines

Sex: All·Age: 18+

Code: NCT05006716·Phase 1, Phase 2·Recruiting·Listed Aug 2021

Apply to this trial

A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy

for Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD)

20 locations incl. Loma Linda

Sponsor: Pierre Fabre Medicament

Sex: All·Age: All ages

Code: NCT03394365·Phase 3·Recruiting·Listed Jan 2018

Apply to this trial

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

for Non-Small Cell Lung Cancer

76 locations incl. Phoenix

Sponsor: Summit Therapeutics

Sex: All·Age: 18+

Code: NCT05899608·Phase 3·Recruiting·Listed Jun 2023

Apply to this trial

A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

for Low Grade Serous Ovarian Cancer

38 locations incl. Phoenix

Sponsor: Verastem, Inc.

Sex: Female·Age: 18+

Code: NCT06072781·Phase 3·Recruiting·Listed Oct 2023

Apply to this trial

A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis

for Myelofibrosis

30 locations incl. Birmingham

Sponsor: Sumitomo Pharma America, Inc.

Sex: All·Age: 18+

Code: NCT04176198·Phase 1, Phase 2·Recruiting·Listed Nov 2019

Apply to this trial

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

for AML

36 locations incl. Gilbert

Sponsor: Kura Oncology, Inc.

Sex: All·Age: 18+

Code: NCT06001788·Phase 1·Recruiting·Listed Aug 2023

Apply to this trial

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

for Locally Advanced Solid Tumors

11 locations incl. Santa Rosa

Sponsor: Turning Point Therapeutics, Inc.

Sex: All·Age: 12+

Code: NCT03093116·Phase 1, Phase 2·Recruiting·Listed Mar 2017

Apply to this trial

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

for Metastatic Head-and-neck Squamous-cell Carcinoma

25 locations incl. Gilbert

Sponsor: AVEO Pharmaceuticals, Inc.

Sex: All·Age: 18+

Code: NCT06064877·Phase 3·Recruiting·Listed Oct 2023

Apply to this trial

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

for Acute Myeloid Leukemia

44 locations incl. Phoenix

Sponsor: Kura Oncology, Inc.

Sex: All·Age: 18+

Code: NCT05735184·Phase 1·Recruiting·Listed Feb 2023

Apply to this trial

CAR-T Long Term Follow Up (LTFU) Study

for Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program

41 locations incl. Duarte

Sponsor: Novartis Pharmaceuticals

Sex: All·Age: 0 - 100

Code: NCT02445222·Phase 3·Recruiting·Listed May 2015

Apply to this trial

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer

for Pancreatic Ductal Adenocarcinoma (PDAC)

16 locations incl. Los Angeles

Sponsor: Verastem, Inc.

Sex: All·Age: 18+

Code: NCT07644559·Phase 2·Recruiting·Listed Jun 12, 2026

Apply to this trial

A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

for Esophageal Squamous Cell Carcinoma

15 locations incl. Denver

Sponsor: IDEAYA Biosciences

Sex: All·Age: 18+

Code: NCT07503808·Phase 1·Recruiting·Listed Mar 2026

Apply to this trial

A Study of TAK-505 in Adults With Solid Tumors

for Malignant Solid Tumors

15 locations incl. Orange

Sponsor: Takeda

Sex: All·Age: 18+

Code: NCT07436728·Phase 1, Phase 2·Recruiting·Listed Feb 2026

Apply to this trial

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

for NSCLC Adenocarcinoma

15 locations incl. Santa Rosa

Sponsor: IDEAYA Biosciences

Sex: All·Age: 18+

Code: NCT07277413·Phase 1·Recruiting·Listed Dec 2025

Apply to this trial

A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors

for Advanced or Metastatic Solid Tumors

15 locations incl. Santa Monica

Sponsor: Takeda

Sex: All·Age: 18+

Code: NCT07205718·Phase 1, Phase 2·Recruiting·Listed Oct 2025

Apply to this trial

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas

for Bladder Cancer

12 locations incl. Duarte

Sponsor: EvolveImmune United, Inc

Sex: All·Age: 18+

Code: NCT07217171·Phase 1·Recruiting·Listed Oct 2025

Apply to this trial

Showing the 40 most relevant of 433 recruiting trials at this site. Browse all with filters →

More research sites in Houston

M D Anderson Cancer Center (272 trials)
Baylor College of Medicine (197 trials)
The University of Texas Health Science Center at Houston (185 trials)
The University of Texas MD Anderson Cancer Center (131 trials)
Houston Methodist Hospital (128 trials)
Texas Children's Hospital (113 trials)
The University of Texas M. D. Anderson Cancer Center (85 trials)
University of Texas MD Anderson Cancer Center (83 trials)
UT MD Anderson Cancer Center (62 trials)
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center (58 trials)

Explore more

Paid clinical trials in Houston, TX · Texas clinical trials